Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial

NCT06881940 is registered in ClinicalTrials.gov with Instituto Nacional de Cardiologia Ignacio Chavez as lead sponsor.

NCT NCT06881940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06881940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
December 1, 2029
Enrollment
284 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer therapy-related cardiac dysfunction